Empresas›INTS

INTS · INTENSITY THERAPEUTICS, INC.

productos biologicos · CIK 0001567264

INTENSITY THERAPEUTICS, INC. (INTS) cotiza en el NASDAQ y se dedica a productos biologicos. Aqui estan 12 documentos que ha presentado ante la SEC, desde 1 jul 2026. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa, contrasplit de acciones y programa de venta continua de acciones (atm). Estan citadas literalmente mas abajo.

Documentos

12

recogidos hasta hoy

Ultimo

11 ago 2026

Informe trimestral

Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.

Documentos presentados ante la SEC

2026

1. 11 ago 202610-QInforme trimestralEDGAR
   Duda sustancial sobre la continuidad de la empresaver la frase en el documento (ingles)

   …and Capital Resources Our financial statements have been prepared assuming we will continue as a going concern. We have incurred losses from operations and negative cash flows from operations that raise substantial doubt about our ability to continue as a going concern. We have financed our operations primarily through an initial investment from our founder, the issuance and sale of convertible debt notes, and private and public equity financings. Since our inception…

   Contrasplit de accionesver la frase en el documento (ingles)

   …The Company’s DfuseRxSM technology platform has identified a lead drug, INT230-6. The Company is based in Connecticut and was incorporated in Delaware in December 2012. On February 19, 2026, the Company effected a 1-for-25 reverse stock split (the “Reverse Stock Split”). Every 25 shares of the Company’s issued and outstanding shares of the Company’s common stock were automatically converted into one share of the Company’s common stock. All…

   Programa de venta continua de acciones (ATM)ver la frase en el documento (ingles)

   …792 $ 634 Accrued employee compensation-related expenses 269 800 Accrued other 142 98 Total $ 1,203 $ 1,532 Note 7. Stockholders’ Equity At The Market Offering Agreement On July 3, 2024, the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may sell and issue, from time to time, up to $15.0 million of shares of its common stock…
2. 11 ago 20268-KHecho relevanteEDGAR
   Programa de venta continua de acciones (ATM)ver la frase en el documento (ingles)

   …in grade 3 adverse events in Cohort A compared with Cohort B and fewer immune-related adverse events when INT230-6 was added prior to the immunochemotherapy. Capital Raises In March 2026, the Company established a $60 million at-the-market (“ATM”) facility. During the second quarter of 2026, the Company raised net proceeds of $1.6 million under the ATM. Subsequent to June 30, 2026, the Company has raised additional net proceeds of $1.3 million under the…
3. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
4. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
5. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
6. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
7. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
8. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
9. 20 jul 20264Operacion de un directivo o accionista significativoEDGAR
10. 8 jul 2026S-8Registro de acciones para empleadosEDGAR
11. 1 jul 20264Operacion de un directivo o accionista significativoEDGAR
12. 1 jul 20264Operacion de un directivo o accionista significativoEDGAR